Drug Trial Radar · NCT00286793
Safety and Efficacy Study of AT-101 in Combination With Docetaxel and Prednisone in Men With HRPC
Last checked: Nov 19, 2026Latest source record: Jun 29, 2011 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
76
Actual
Start
Feb 2006
Primary completion
Nov 2009
Study completion Nov 2009
Sponsor
- Lead sponsor
- Ascenta TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Feb 6, 2006
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- Male only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open-label, multicenter Phase I/II study to evaluate the safety and efficacy of AT-101 in combination with docetaxel and prednisone in men with hormone-refractory prostate cancer that are either chemotherapy naive or have received and progressed on a docetaxel containing regimen,
Conditions
- Prostate Cancer
Interventions
AT-101Drug
Oral
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety of AT-101 in combination with docetaxel and prednisoneTime frame: 12 months
Locations
13 sites in 1 country. Site status is shown where the registry gives one.
Site not named
Hot Springs, Arkansas
Site not named
Fort Meyers, Florida
Site not named
Chicago, Illinois
Site not named
Fridley, Minnesota
Site not named
Albuquerque, New Mexico
Site not named
Syracuse, New York
Site not named
Wilmington, North Carolina
Site not named
Portland, Oregon
Site not named
Hilton Head Island, South Carolina
Site not named
Germantown, Tennessee
Site not named
Memphis, Tennessee
Site not named
Nashville, Tennessee
Site not named
Richardson, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.